Circassia Pharmaceuticals, a British company with U.S. headquarters in Morrisville, has commercially launched Duaklir, a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD), in the United States.
Read More
Circassia Pharmaceuticals, a British company with U.S. headquarters in Morrisville, has received an industry award and signed a group purchasing agreement for its asthma products.
Read More
Circassia Pharmaceuticals, a British company with U.S. headquarters in Morrisville, has received U.S. Food and Drug Administration approval of Duaklir Pressair, a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).
Read More
Circassia Pharmaceuticals, a British company with U.S. headquarters in Morrisville, will acquire the exclusive commercialization rights to a life-saving medical device for newborns facing a potentially deadly respiratory condition.
Read More
MORRISVILLE -=Circassia Pharmaceuticals, a British company with U.S. headquarters in Morrisville, plans to acquire the full U.S. commercial rights to Tudorza, a treatment for chronic obstructive pulmonary disease (COPD) from British drug-maker AstraZeneca by the end of this month. Circassia, a specialty pharmaceutical company focused on respiratory disease, has...
Read More
Circassia is breathing a sigh of relief over a decision by the giant AETNA health insurance company that one of Circassia’s key asthma products is “medically necessary.”
Read More
Aetna has determined that a breath test for asthma patients is medically necessary.
Read More
